Purdue David Ryan 4

What Happened

• David Ryan Purdue, Senior Vice President and Controller of AbbVie (ABBV), was credited with a total of 10,946 shares through awards and an account balance on Feb 18, 2026. The filing lists awards of 2,505; 890; 1,292; and 1,384 shares (all $0 per share, performance-vested awards) plus 4,875 shares reported as a derivative balance. These awards/prior holdings have a reported acquisition price of $0 and will be issued or reflected on Feb 28, 2026. The performance-vesting conditions for the awards were certified by AbbVie’s Compensation Committee and released on Feb 18, 2026.

Key Details

• Transaction date(s): Feb 18, 2026; Form 4 filed Feb 20, 2026 (appears timely).
• Shares granted/credited: 2,505 + 890 + 1,292 + 1,384 + 4,875 = 10,946 shares; acquisition price reported $0.
• Issuance date: The performance-based shares from the awards are scheduled to be issued on Feb 28, 2026 (see footnotes).
• Notable footnotes:
  • F1–F4: Four performance-vesting awards (granted in 2023–2025) whose performance conditions were certified and released; shares to be issued Feb 28, 2026.
  • F5: 4,875-share balance in the AbbVie Savings program as of Feb 20, 2026 (includes dividend reinvestment).
  • F6: Filing also references an employee stock option award under the company plan with staged exercisability (1,625 shares each year on Feb 18, 2027–2029).
• Shares owned after transaction: The filing does not specify total post-transaction beneficial ownership in this summary line.

Context

• These transactions are awards and an account balance being recorded/issued, not open-market purchases or sales. Performance-based awards reflect achievement of pre-set metrics (e.g., EPS, relative TSR, or return on equity per the footnotes) and do not necessarily indicate an insider’s immediate trading intent. The derivative designation on the 4,875 shares reflects reporting of a savings-plan balance rather than a new cash purchase.